CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Availability of generic versions of autoinjectors
4.1.2. Increasing number of regulatory approvals
4.1.3. Technological advancements and design development
4.1.4. Rising incidence of anaphylaxis
4.1.5. Growing prevalence of targeted therapies
4.2. Market Restraints & Challenges
4.2.1. Preference for alternative drug delivery modes
4.2.2. Lack of proper training for using autoinjectors
4.2.3. Development of autoinjectors for multiple drug viscosities
CHAPTER 5. GLOBAL AUTOINJECTORS MARKET – BY THERAPY
5.1. Diabetes
5.2. Anaphylaxis
5.3. Multiple Sclerosis
5.4. Rheumatoid Arthritis
5.5. Others
CHAPTER 6. GLOBAL AUTOINJECTORS MARKET – BY TYPE
6.1. Disposable Autoinjectors
6.2. Reusable Autoinjectors
CHAPTER 7. GLOBAL AUTOINJECTORS MARKET – BY END USER
7.1. Home Care Settings
7.2. Hospitals & Clinics
7.3. Others
CHAPTER 8. GLOBAL AUTOINJECTORS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL AUTOINJECTORS MARKET - COMPANY PROFILES
9.1. Abbvie Inc.
9.2. Mylan Ltd
9.3. Eli Lilly and Company
9.4. Ypsomed Holdings
9.5. Amgen Inc.
9.6. Becton, Dickinson and Company
9.7. Owen Mumford Ltd.
9.8. Consort Medical PLC
9.9. Haselmeier Group
9.10. SHL Group (Scandinavian Health Limited)
9.11. Johnson & Johnson (J&J) PLC
9.12. Teva Pharmaceutical Industries Ltd
9.13. Antares Pharma, Inc.
CHAPTER 10. GLOBAL AUTOINJECTORS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
